GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
1.270
-0.180 (-12.41%)
Aug 15, 2025, 10:25 AM - Market open
GT Biopharma Stock Forecast
GTBP's stock price has decreased by -52.84% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for GT Biopharma stock has a target of 11, which predicts a 766.14% increase from the current stock price of 1.27.
Price Target: $11 (+766.14%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 2, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for GT Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +766.14% | Dec 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +11,711.02% | Aug 8, 2023 |
| EF Hutton | EF Hutton | Hold Reiterates $60 | Hold | Reiterates | $60 | +4,624.41% | Aug 7, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +11,711.02% | Jun 5, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +11,711.02% | May 17, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.99
from -6.94
EPS Next Year
-1.04
from -1.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.05 | -1.07 | -0.90 |
| Avg | -1.99 | -1.04 | -0.88 |
| Low | -1.91 | -1.00 | -0.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.